Recombinant Bacillus subtilis spores expressing MPT64 evaluated as a vaccine against tuberculosis in the murine model

FEMS Microbiology Letters

Volumn 358, Issue 2, 2014, Pages 170-179

  Sibley, Laura ^a   Reljic, Rajko ^b   Radford, David S ^c,d,e   Huang, Jen Min ^a   Hong, Huynh A ^a   Cranenburgh, Rocky M ^d   Cutting, Simon M ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Keele Science Park   (United Kingdom)

^d Prokarium Ltd   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Mucosal vaccine; TB; Tuberculosis; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CYTOKINE; FORMALDEHYDE; HYBRID PROTEIN; INACTIVATED VACCINE; LIVE VACCINE; PROTEIN COTB; PROTEIN MPT64; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; COTB PROTEIN, BACILLUS SUBTILIS; DRUG CARRIER; MPT64 PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; BACILLUS SUBTILIS; BACTERIAL GENE; BACTERIAL LOAD; BACTERIAL SPORE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; COTB GENE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOSTIMULATION; LETTER; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; T LYMPHOCYTE; TH1 CELL; ANIMAL; C57BL MOUSE; CELL SURFACE DISPLAY; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOLOGY; LUNG; MICROBIOLOGY; PROCEDURES; SECRETION (PROCESS); TUBERCULOSIS; VACCINATION;

BACILLUS SUBTILIS; BACTERIA (MICROORGANISMS); MURINAE; MUS;

ANIMALS; ANTIGENS, BACTERIAL; BACILLUS SUBTILIS; BACTERIAL LOAD; BACTERIAL PROTEINS; CELL SURFACE DISPLAY TECHNIQUES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; LUNG; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SPORES, BACTERIAL; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 84927784112     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12525     Document Type: Letter

References (35)

1. Behr MA & Small PM (1999) A historical and molecular phylogeny of BCG strains. Vaccine 17: 915-922.
2. Beveridge NE, Price DA, Casazza JP et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
3. Bloor AE & Cranenburgh RM (2006) An efficient method of selectable marker gene excision by Xer recombination for gene replacement in bacterial chromosomes. Appl Environ Microbiol 72: 2520-2525.
4. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG & Orme IM (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243-2247.
5. Donovan W, Zheng L, Sandman K & Losick R (1987) Genes encoding spore coat polypeptides from Bacillus subtilis. J Mol Biol 196: 1-10.
6. Duc LH, Hong HA, Fairweather N, Ricca E & Cutting SM (2003) Bacterial spores as vaccine vehicles. Infect Immun 71: 2810-2818.
7. Duc LH, Hong HA, Uyen NQ & Cutting SM (2004) Intracellular fate and immunogenicity of B. subtilis spores. Vaccine 22: 1873-1885.
8. Duc LH, Hong HA, Atkins HS, Flick-Smith HC, Durrani Z, Rijpkema S, Titball RW & Cutting SM (2007) Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 25: 346-355.
9. EDQM (2014) European Pharmacopoeia, 8th edn. European Directorate for the Quality of Medicines & Healthcare, Council of Europe, France.
10. Gampfer J, Thon V, Gulle H, Wolf HM & Eibl MM (2002) Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine 20: 1354-1364.
11. Hartl B, Wehrl W, Wiegert T, Homuth G & Schumann W (2001) Development of a new integration site within the Bacillus subtilis chromosome and construction of compatible expression cassettes. J Bacteriol 183: 2696-2699.
12. Henriques AO & Moran CP Jr (2007) Structure, assembly, and function of the spore surface layers. Annu Rev Microbiol 61: 555-588.
13. Hoang TH, Hong HA, Clark GC, Titball RW & Cutting SM (2008) Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis. Infect Immun 76: 5257-5265.
14. Hong HA, Duc le H & Cutting SM (2005) The use of bacterial spore formers as probiotics. FEMS Microbiol Rev 29: 813-835.
15. Hong HA, To E, Fakhry S, Baccigalupi L, Ricca E & Cutting SM (2009a) Defining the natural habitat of Bacillus spore-formers. Res Microbiol 160: 375-379.
16. Hong HA, Khaneja R, Tam NM, Cazzato A, Tan S, Urdaci M, Brisson A, Gasbarrini A, Barnes I & Cutting SM (2009b) Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol 160: 134-143.
17. Huang JM, Hong HA, Van Tong H, Hoang TH, Brisson A & Cutting SM (2010a) Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 28: 1021-1030.
18. Huang JM, Sali M, Leckenby MW, Radford DS, Huynh HA, Delogu G, Cranenburgh RM & Cutting SM (2010b) Oral delivery of a DNA vaccine against tuberculosis using operator-repressor titration in a Salmonella enterica vector. Vaccine 28: 7523-7528.
19. Isticato R, Cangiano G, Tran HT, Ciabattini A, Medaglini D, Oggioni MR, De Felice M, Pozzi G & Ricca E (2001) Surface display of recombinant proteins on Bacillus subtilis spores. J Bacteriol 183: 6294-6301.
20. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J & Amara RR (2007) Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 81: 12071-12076.
21. Mauriello EM, Duc le H, Isticato R, Cangiano G, Hong HA, De Felice M, Ricca E & Cutting SM (2004) Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Vaccine 22: 1177-1187.
22. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA & Hill AV (2005) Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 85: 47-52.
23. Nicholson WL & Setlow P (1990) Sporulation, germination and outgrowth. Molecular Biological Methods for Bacillus (Harwood CR & Cutting SM, eds), pp. 391-450. John Wiley & Sons Ltd., Chichester, UK.
24. Odutola AA, Owolabi OA, Owiafe PK, McShane H & Ota MO (2012) A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. Vaccine 30: 5591-5594.
25. Pellegrini V, Fineschi N, Matteucci G, Marsili I, Nencioni L, Puddu M, Garelick H & Zuckerman AJ (1993) Preparation and immunogenicity of an inactivated hepatitis A vaccine. Vaccine 11: 383-387.
26. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF & Cutting SM (2011) Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79: 2295-2302.
27. Reljic R, Sibley L, Huang JM, Pepponi I, Hoppe A, Hong HA & Cutting SM (2013) Mucosal vaccination against tuberculosis using inert bioparticles. Infect Immun 81: 4071-4080.
28. Rowland R, Brittain N, Poulton ID et al. (2012) A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials Vaccinol 1: 27-35.
29. Sali M, Dainese E, Morandi M, Zumbo A, Rocca S, Goussard S, Palu G, Grillot-Courvalin C, Delogu G & Manganelli R (2014) Homologous prime boosting based on intranasal delivery of non-pathogenic invasive Escherichia coli expressing MPT64, decreases Mycobacterium tuberculosis dissemination. Vaccine 32: 4051-4058.
30. Salk D & Salk J (1984) Vaccinology of poliomyelitis. Vaccine 2: 59-74.
31. Sharpe SA, McShane H, Dennis MJ et al. (2010) Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol 17: 1170-1182.
32. Song M, Hong HA, Huang JM et al. (2012) Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine. Vaccine 30: 3266-3277.
33. Twomey T, Newman J, Burrage T, Piatti P, Lubroth J & Brown F (1995) Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13: 1603-1610.
34. Wang C, Chen Z, Fu R, Zhang Y, Chen L, Huang L, Li J, Shi C & Fan X (2011) A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice. Med Microbiol Immunol 200: 165-175.
35. White AD, Sibley L, Dennis MJ et al. (2013) Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol 20: 663-672.